

Special Issue

Radiosurgery for Brain Tumors

Message from the Guest Editor

The incidence of cancer is increasing worldwide. As a noninvasive alternative to surgery, radiosurgery uses high-energy X-rays or protons to destroy tumors. As one of the treatment modalities, radiosurgery plays a crucial role in managing malignant brain tumors. Radiosurgery can also be used for the effective treatment of benign brain tumors such as meningiomas or pituitary adenoma. Stereotactic radiosurgery (SRS) uses many precisely focused radiation beams for the accurate targeting of tumors while minimizing damage to the surrounding organs at risk, such as healthy brain tissue, brain stem, chiasm, optic nerves, eyes, the cochlea, and pituitary gland. Nowadays, magnetic resonance imaging (MRI) has significantly improved the delineation of brain tumors and has allowed for progress to be made in terms of irradiation using magnetic resonance linac (MRL). We cordially invite you to submit your cutting-edge research and review articles to this Special Issue, which aims to encompass new research articles and timely reviews on all aspects of brain tumors' radiosurgery treatment with photons or protons.

Guest Editor

Dr. Anna Petoukhova

Department of Medical Physics, Haaglanden Medical Center, 2262 BA Leidschendam, The Netherlands

Deadline for manuscript submissions

31 July 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/203671

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)